IDEAL-CRT: A phase I/II trial of isotoxic dose-escalated radiotherapy and concurrent chemotherapy in patients with stage II/III non-small cell lung cancer

Publication date: Available online 28 March 2016
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): David B. Landau, Laura Hughes, Angela Baker, Andrew T. Bates, Michael C. Bayne, Nicholas Counsell, Ange Garcia-Alonso, Susan V. Harden, Jonathan D. Hicks, Simon R. Hughes, Marianne C. Illsley, Iftekhar Khan, Virginia Laurence, Zafar Malik, Helen Mayles, William PM. Mayles, Elizabeth Miles, Nazia Mohammed, Yenting Ngai, Emma Parsons, James Spicer, Paula Wells, Dean Wilkinson, John D. Fenwick
Backgroundand Purpose: Toxicity and early efficacy data are presented for IDEAL-CRT, a trial of an escalated, concurrent chemoradiotherapy schedule for advanced stage non-small cell lung cancer (NSCLC). Tumor dose-per-fraction-escalation was used in IDEAL-CRT to achieve therapy intensification without prolongation, and tumor doses were prescribed isotoxically to maximum levels consistent with normal tissue dose constraints.Patients and MethodsPatients received tumor doses of 63-73Gy in 30 once-daily fractions over 6 weeks with two concurrent cycles of cisplatin and vinorelbine. They were assigned to one of two groups according to esophageal dose. In Group 1, tumor doses were determined by an experimental constraint on maximum esophageal dose which was escalated following a 6+6 design from 65Gy through 68Gy to 71Gy, allowing an esophageal maximum tolerated dose (MTD) to be determined from early and late toxicities. Tumor doses for Group 2 patients were determined by other tissue constraints, often lung. Overall survival (OS), progression-free survival (PFS), tumor response and toxicity were evaluated for both groups combined.ResultsEight centres recruited 84 patients: 13, 12 and 10 in the 65Gy, 68Gy and 71Gy cohorts of Group 1, and 49 in Group 2. The mean prescribed tumor dose was 67.6Gy. Five grade 3 esophagitis and three grade 3 pneumonitis events were observed across both groups. Following one fatal esophageal perforation in the 71Gy cohort, 68Gy was declared the esophageal MTD. With a median follow-up of 35 months, median OS was 36.9 months, and OS and PFS were 87.8% and 72.0% at 1 year and 68.0% and 48.5% at 2 years.ConclusionsIDEAL-CRT achieved significant treatment intensification with acceptable toxicity and promising survival. The isotoxic design allowed the esophageal MTD to be identified from relatively few patients.

Teaser

Eighty-four patients (6 IIB, 57 IIIA, 21 IIIB) were recruited to IDEAL-CRT, an early phase trial of dose-per-fraction-escalated concurrent chemoradiation for NSCLC. Tumor doses of 63-73Gy (mean 67.6Gy) were isotoxically prescribed to the ICRU reference-point and delivered in 30 fractions over 40 days. Toxicity was acceptable. At 35 months median follow-up, median OS was 36.9 months, 1 year OS and PFS were 87.8% and 72.0%, and 2 year OS and PFS were 68.0% and 48.5%.


from Cancer via ola Kala on Inoreader http://ift.tt/1RBwaMD
via IFTTT